CliffBio
biologic

Lerochol

lerodalcibep-liga

Loss of exclusivityAugust 2038projected — 12-year biologic exclusivity estimate
CompanyLIB Therapeutics, Inc.

Drug detail

Brand nameLerochol
Active ingredientlerodalcibep-liga
Strength300MG/1.2ML (250MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2026
Marketing statusRx

More from LIB Therapeutics, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lerochol patent cliff — loss of exclusivity August 2038 | CliffBio